Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
he US FDA has issued six observations pursuant to the completion of the audit.
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)